Promoter hypermethylation of GSTP1, AR, and 14-3-3σ in serum of prostate cancer patients and its clinical relevance

The Prostate ◽  
2007 ◽  
Vol 67 (4) ◽  
pp. 427-432 ◽  
Author(s):  
Jochen Reibenwein ◽  
Dietmar Pils ◽  
Peter Horak ◽  
Birgit Tomicek ◽  
Gregor Goldner ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Clinical Relevance ◽  
Promoter Hypermethylation

scholarly journals RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy

Oncotarget ◽  
2016 ◽  
Vol 8 (4) ◽  
pp. 5774-5788 ◽  
Author(s):  
Siri H. Strand ◽  
Michal Switnicki ◽  
Mia Moller ◽  
Christa Haldrup ◽  
Tine M. Storebjerg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Biochemical Recurrence ◽  
Promoter Hypermethylation

520 Promoter Hypermethylation of HIST1H4K and RASSF2 in Urine From Prostate Cancer Patients

2012 ◽  
Vol 48 ◽  
pp. S123-S124
Author(s):  
D. Kachakova ◽  
E. Popov ◽  
A. Mitkova ◽  
O. Beltcheva ◽  
A. Vlahova ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Promoter Hypermethylation

scholarly journals Detection of Circulating Tumor Cells in Prostate Cancer Patients: Methodological Pitfalls and Clinical Relevance

2009 ◽  
Vol 15 (3-4) ◽  
pp. 101-114 ◽  
Author(s):  
Zacharoula Panteleakou ◽  
Peter Lembessis ◽  
Antigone Sourla ◽  
Nikolaos Pissimissis ◽  
Aristides Polyzos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Relevance

scholarly journals Multimarker Circulating DNA Assay for Assessing Blood of Prostate Cancer Patients

2009 ◽  
Vol 55 (3) ◽  
pp. 559-567 ◽  
Author(s):  
Eiji Sunami ◽  
Masaru Shinozaki ◽  
Celestia S Higano ◽  
Robert Wollman ◽  
Tanya B Dorff ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Specific Antigen ◽  
Promoter Hypermethylation ◽  
Circulating Dna ◽  
Epigenetic Changes ◽  
Negative Results ◽  
Specific Pcr ◽  
Ajcc Stage ◽  
Dna Assays

Abstract Background: Prostate cancer (PCa) detection using serum-based prostate specific antigen (PSA) is limited by frequent false-positive and -negative results. Genetic aberrations such as allelic imbalance (AI) and epigenetic changes such as promoter hypermethylation have been detected in circulating DNA of cancer patients. We hypothesized that circulating multimarker DNA assays detecting both genetic and epigenetic markers in serum would be useful in assessing PCa patients. Methods: We assayed blood from healthy male donors (n = 40) and 83 patients with American Joint Cancer Committee (AJCC) stage I–IV PCa. DNA was assayed for AI of 6 genome microsatellites. We assessed methylation of RASSF1, RARB2, and GSTP1 using a methylation-specific PCR assay and analyzed the sensitivity of each assay for the detection of genetic or epigenetic changes in circulating DNA. The relation between circulating tumor-related DNA detection and prognostic factors was investigated. Results: The proportion of patients demonstrating AI for ≥1 marker was 47% (38 of 81 patients). Methylation biomarkers were detected in 24 of 83 patients (28%). By combining 2 DNA assays, the number of PCa patients positive for ≥1 methylated or LOH marker increased (52 of 83; 63%). The combined assays detected PCa in 15 of 24 patients (63%) with normal PSA concentrations. The combination of the DNA assays detected the presence of PCa regardless of AJCC stage or PSA concentration. Combination of the DNA and PSA assays gave 89% sensitivity. Conclusions: This pilot study demonstrates that the combined circulating DNA multimarker assay identifies patients with PCa and may yield information independent of AJCC stage or PSA concentration.

390: Durable Cancer Control in High Risk Prostate Cancer Patients Treated with Radical Prostatectomy

2007 ◽  
Vol 177 (4S) ◽  
pp. 130-130
Author(s):  
Markus Graefen ◽  
Jochen Walz ◽  
Andrea Gallina ◽  
Felix K.-H. Chun ◽  
Alwyn M. Reuther ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Cancer Control ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

598: Increased Risk of Newly Diagnosed Comorbidities in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 200-200 ◽  
Author(s):  
Andrea Gallina ◽  
Pierre I. Karakiewicz ◽  
Jochen Walz ◽  
Claudio Jeldres ◽  
Quoc-Dien Trinh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Increased Risk

289: Assessment of Indirect Costs of Newly Diagnosed Prostate Cancer Patients

2007 ◽  
Vol 177 (4S) ◽  
pp. 97-97
Author(s):  
Ravishankar Jayavedappa ◽  
Sumedha Chhatre ◽  
Richard Whittington ◽  
Alan J. Wein ◽  
S. Bruce Malkowicz
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Indirect Costs ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document